1 Min Read
Oct 30 (Reuters) - Bayer AG
* Bayer - U.S. FDA accepted co’s BLA filing for bay94-9027 for treatment of Hemophilia A in adults and adolescents 12 years of age and over Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.